Group 1 - Jiangsu Chuangjian Medical Technology Co., Ltd. (Chuangjian Medical) has officially announced the termination of its listing on the National Equities Exchange and Quotations (NEEQ) after just 271 days, marking a rapid exit from the capital market [1][2] - The company initiated its listing process in early 2024, signed a contract with CITIC Securities, and officially listed on NEEQ on November 11, 2024, becoming the third collagen-restructured enterprise to do so [2] - The decision to withdraw may stem from a strategic shift, allowing the company to avoid the disclosure pressures and compliance costs associated with being a public company during a critical period of technological breakthroughs in collagen [2][3] Group 2 - Prior to its delisting, Chuangjian Medical received two core patent authorizations related to collagen technology, indicating a strong focus on innovation and potential market applications in the medical beauty sector [2] - The company has formed a strategic partnership with a leading global cosmetics OEM, Kosei Meishi, to develop new regenerative medical materials, suggesting a pivot towards business-to-business (B2B) opportunities [2][3] - The broader trend of medical companies exiting the NEEQ highlights a common challenge in the industry, where compliance costs and liquidity issues are increasingly burdensome, leading to a significant rise in delistings [3][4] Group 3 - The exit of Chuangjian Medical is part of a larger trend, with a 40% year-on-year increase in delistings among biomedicine companies on NEEQ in the first half of 2025, indicating a significant capital withdrawal from the sector [4] - The company’s strategy emphasizes enhancing product innovation and leveraging technological advancements to attract strategic investments, potentially positioning itself for future growth in higher-tier capital markets [4]